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ABSTRACT 
 
Aims: Serotonin syndrome is a potentially life-threatening drug interaction caused by excess 
serotonin concentration in the central nervous system and/or peripheral nervous system leading to 
cognitive, autonomic and somatic effects ranging from barely perceptible to fatal. A number of drugs 
and drug interactions cause serotonin syndrome, however, the exact mechanisms often remain 
elusive.  
Presentation of Case: In the following case, serotonin syndrome was caused by the addition of 
pregabalin in a patient with recurrent major depressive disorder and concurrent medication with 
paroxetine and trazodone.  
Discussion: This case illustrates the risk of polypsychopharmacology leading to an increased 
vulnerability towards serotonin syndrome.  
Conclusion: Pregabalin with its serotonergic action has a liability to cause serotonin syndrome. 
This should be especially kept in mind in patients with polypsychopharmacology. 
  
Case Study 
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1. INTRODUCTION  
 
Serotonin syndrome (SS) is a potentially life-
threatening drug interaction caused by excess 
serotonin in the central nervous system (CNS) 
and/or peripheral nervous system. As a 
consequence, excess serotonin causes cognitive 
alterations, ranging from headache to 
hypomania, agitation, confusion, hallucination or 
coma, and autonomic dysregulation with 
shivering, sweating, hyperthermia, tachycardia, 
hypertension, nausea, and diarrhea, as well as 
somatic, in particular, neurological alterations 
such as tremor, hyperreflexia and myoclonus [1]. 
The presenting symptomatology varies from 
barely perceptible, then often not acknowledged, 
to fatal.  
 
Serotonin syndrome is caused by a variety of 
pharmacological mechanisms. Among these are 
the inhibition of serotonin reuptake, decreased 
serotonin metabolism, increased serotonin 
synthesis and release, and activation of 
serotonergic receptors [2]. Another mechanism 
increasing the risk for SS is the Cytochrome 
P450 system, in particular, the inhibition of 
CYP450 2D6 [3]. Clinically, SS is often caused 
by an overdose of single serotonergic agents 
such as selective serotonin reuptake inhibitors 
(SSRIs), however, more frequently from drug-
drug interactions of several serotonergic agents. 
In particular, monoamine oxidase inhibitors 
(MAOI) have been associated with this syndrome 
alongside other antidepressants such as tricyclic 
antidepressants (TCA), serotonin reuptake 
inhibitors (SSRI), serotonin-norepinephrine 
reuptake inhibitors (SNRI), bupropion, trazodone 
and mirtazapine, opioids with frequent reports on 
tramadolol, CNS stimulants, 5HT1-agonists such 
as triptans, herbs, in particular hypericum (St. 
John’s wort), and others such as valproate, 
lithium, or atypical antipsychotics. 
 
Pathophysiologically, it was primarily suspected 
that the 5HT1a receptor system was involved in 
this syndrome, later, the 5HT2a receptor site has 
been identified as another contributing system, 
and, at last, an increase in norepinephrine levels 
was documented [4]. 
 
Further, various neurotransmitters have been 
implicated in the emergence of the SS including 
the N-Methyl-D-Aspartate (NMDA) - receptor, 
namely, antagonists at this receptor site such as 
gamma-amino-butyric acid (GABA) and 
dopamine [5]. 
 
2. PRESENTATION OF CASE 
 
Mrs. E. is a 45-year-old patient with a recurrent 
major depressive disorder, posttraumatic stress 
disorder (PTSD), opiate dependence on 
methadone maintenance, a combined personality 
disorder, and chronical medically unexplained 
symptoms with multilocular pain symptoms, 
nausea, obstipation and chronic fatigue 
indicating a somatization disorder.  
 
The patient was psychiatrically hospitalized due 
to an exacerbation of depression and pain. She 
was on leave over the weekend when she 
experienced a change in mental status with 
disturbances of consciousness and cognition, as 
well as tremor and myoclonus of the upper and 
lower extremities, headache, and diaphoresis. 
With further aggravation of these symptoms on 
the following day she was urgently transferred to 
the University Hospital Zurich for further 
evaluation and management. The primary 
assessment revealed an inconspicuous head 
computertomography scan, renal failure with 
decreased glomerular filtration rate (GFR: 44 
ml/min), elevated inflammatory parameters (C-
reactive protein 66 mg/l), elevation of ammonia 
40 umol/l, upper and lower extremity clonus, 
resting tremor of the hands, and sedation. At the 
time of admission, the patient was on a stable 
psychotropic regimen of paroxetine 50 mg, 
trazodone 50 mg, bupropion XR 450 mg, 
paliperidone 6 mg and methadone 7.5 mg. Due 
to her multiple physical complaints with varying 
pain symptoms an antinociceptive strategy with 
pregabalin was initiated and gradually increased 
within the following weeks, reaching 750 mg on 
the day of admission. During the first night of 
hospitalization, Mrs. E. presented with a single 
episode of acute dyspnea and arterial 
hypoxemia. The chest radiography was normal, 
following oxygen application via face mask, 
administration of 125 mg methylprednisolone per 
os, and of 2.2 g of amoxicillin/clavulanic 
intravenously to cover infectious etiologies, the 
hypoxemia resolved, and the patient was 
transferred back to the regular floor. Her 
hemodynamic profile remained stable over the 
course of management.  
 
The clinical presentation was highly suggestive 
of a serotonin syndrome, consequently, 
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trazodone and bupropion were discontinued, 
paroxetine was reduced to 10 mg and pregabalin 
to 700 mg. Within the next 48 hours, the mental 
disturbances and neuromuscular symptoms 
remitted, and the patient was transferred back to 
psychiatric hospital. 
 
3. DISCUSSION 
 
In this case, SS was triggered by the 
administration of pregabalin on top of a stable 
regimen of paroxetine, trazodone, bupropion, 
and paliperidone, all of which have been 
associated with SS [6-8].  
 
Gabapentin, an analogue of pregabalin, has 
been shown to increase serotonin levels in the 
CNS [9]. Only one case report has described SS 
in the context of pregabalin co-administration to 
oxycodone preoperatively [10]. It was deducted 
that pregabalin, increasing the whole blood 
serotonin concentration in therapeutic dose 
ranges, in combination with oxycodone, was 
associated with an increased risk of developing 
SS. It is known that opioids beyond effects on the 
opioid system, also cause an increase of 
serotonin in the CNS through serotonin reuptake 
inhibition [11,12], thus, potentially causing SS 
[13]. In this case, the patient was on a stable 
regimen of methadone, which might have been 
an additional contributing factor for the 
development of SS, in addition to pregabalin at a 
substantial dose in combination with other 
serotonergic agents. Further, the patient’s initial 
presentation with renal failure and a decrease in 
GFR were potential contributors to pregabalin 
accumulation and subsequent serotonin 
syndrome, since the renal pathway is the primary 
route of pregabalin elimination.  
 
SS involves a spectrum of clinical findings 
presenting with the typical triad of SS features:  
1) mental status changes 2) autonomic 
dysfunction and 3) neuromuscular excitability [1].  
 
The diagnosis is made based on the clinical 
presentation according to the Hunter criteria [14]. 
These criteria state that a serotonergic agent has 
to be present in addition to either of the following 
clinical findings: Spontaneous clonus; inducible 
clonus and agitation; ocular clonus and agitation; 
tremor and hyperreflexia; hypertonia and an 
increased temperature (>38°C) and ocular or 
inducible clonus. In Mrs. E’s case the diagnostic 
criteria were met with occurrence of a 
spontaneous clonus under serotonergic 
polypsychopharmacology. Another factor 
predisposing to the episode of hypoventilation 
and hypoxemia could have been thoracic rigidity 
caused by SS. 
 
In the presence of polypsychopharmacology, this 
case illustrates that the addition of a single agent 
– pregabalin - can increase the risk for serotonin 
syndrome. Combining serotonergic agents like 
antidepressants or opioids can cause excessive 
stimulation of the 5HT1a and 5HT2a receptors 
[15]. 
 
Targeting common and preventable adverse 
drug reactions and drug-drug interactions is 
crucial in ensuring patient safety and is even 
more challenging in susceptible sub-populations 
with polypsychopharmacology. Consequently, 
increasing research efforts  have been initiated in 
order to enhance the knowledge on adverse drug 
reactions, including clinical decision support 
systems, databases on drug-target interactions 
and drug-drug interactions, as well as 
pharmacogenomic approaches (see [16] for a 
recent overview).  
 
4. CONCLUSION 
 
In summary, this is another case, illustrating the 
incidence of SS following the addition and 
titration of pregabalin on top of a stable regimen 
of psychotropics including serotonergic agents, in 
this case, paroxetine, trazodone, bupropion, 
paliperidone, and methadone. Although this 
patient had already been predisposed to SS due 
to her polypsychopharmacology administered 
prior to the development of SS, the addition of 
pregabalin, with its serotonergic action, triggered 
the onset of this syndrome. To date, pregabalin 
has not often been associated with SS, however, 
it is important, to keep its liability to cause SS in 
mind.  
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